Satvat Ali J.
Insider CIK 1621788 · CHRS Director · EIDX Director, 10% owner · BBIO Director, 10% owner
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| BBIO BridgeBio Pharma, Inc. | A Award deriv | 2026-06-22 | 2026-06-24 | 5,277 | — | $0 | 5,277 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | A Award | 2026-06-22 | 2026-06-24 | 3,990 | — | $0 | 169,983 | SEC↗ |
| CHRS Coherus Oncology, Inc. | A Award deriv | 2026-06-05 | 2026-06-09 | 60,000 | — | $0 | 60,000 | SEC↗ |
| CHRS Coherus Oncology, Inc. | A Award | 2026-06-05 | 2026-06-09 | 30,000 | — | $0 | 30,000 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | A Award deriv | 2025-06-20 | 2025-06-24 | 8,425 | — | $0 | 8,425 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | A Award | 2025-06-20 | 2025-06-24 | 6,589 | — | $0 | 165,993 | SEC↗ |
| CHRS Coherus Oncology, Inc. | A Award deriv | 2025-06-12 | 2025-06-13 | 112,000 | — | $0 | 112,000 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | M Exercise deriv | 2024-12-30 | 2024-12-31 | 39,851 | — | $0 | 0 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | M Exercise deriv | 2024-12-30 | 2024-12-31 | 39,851 | — | $0 | 0 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | M Exercise deriv | 2024-12-30 | 2024-12-31 | 79,702 | — | $0 | 0 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | M Exercise | 2024-12-30 | 2024-12-31 | 39,851 | $26.21 | $1.04M | 159,404 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | M Exercise | 2024-12-30 | 2024-12-31 | 39,851 | $16.68 | $664.7K | 119,553 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | M Exercise | 2024-12-30 | 2024-12-31 | 79,702 | $10.99 | $875.9K | 79,702 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | A Award deriv | 2024-06-21 | 2024-06-25 | 26,014 | — | $0 | 26,014 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | A Award deriv | 2023-06-21 | 2023-06-23 | 51,501 | — | $0 | 51,501 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | A Award deriv | 2022-06-22 | 2022-06-24 | 104,921 | — | $0 | 104,921 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | A Award deriv | 2021-06-17 | 2021-06-22 | 38,895 | — | $0 | 38,895 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | D To issuer deriv | 2021-01-26 | 2021-01-28 | 21,528 | — | $0 | 0 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | D To issuer deriv | 2021-01-26 | 2021-01-28 | 21,528 | — | $0 | 0 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | D To issuer deriv | 2021-01-26 | 2021-01-28 | 43,056 | — | $0 | 0 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | A Award deriv | 2021-01-26 | 2021-01-28 | 39,851 | — | $0 | 39,851 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | A Award deriv | 2021-01-26 | 2021-01-28 | 79,702 | — | $0 | 79,702 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | A Award deriv | 2021-01-26 | 2021-01-28 | 39,851 | — | $0 | 39,851 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | A Award deriv | 2020-06-02 | 2020-06-04 | 112,422 | — | $0 | 112,422 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | A Award deriv | 2020-05-27 | 2020-05-29 | 21,528 | — | $0 | 21,528 | SEC↗ |
| CHRS Coherus BioSciences, Inc. | A Award deriv | 2020-01-10 | 2020-01-14 | 20,000 | — | $0 | 20,000 | SEC↗ |
| BBIO BridgeBio Pharma, Inc. | A Award deriv | 2019-12-12 | 2019-12-16 | 82,878 | — | $0 | 82,878 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | P Buy | 2019-07-03 | 2019-07-08 | 882,353 | $29.90 | $26.38M | 24,575,501 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | A Award deriv | 2019-06-12 | 2019-06-13 | 21,528 | — | $0 | 21,528 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | P Buy | 2019-05-24 | 2019-05-29 | 1,103,848 | $25.93 | $28.62M | 23,693,148 | SEC↗ |
| CHRS Coherus BioSciences, Inc. | A Award deriv | 2019-01-11 | 2019-01-30 | 20,000 | — | $0 | 20,000 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | A Award deriv | 2018-07-01 | 2018-07-03 | 43,056 | — | $0 | 43,056 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | X Exercise deriv | 2018-06-22 | 2018-06-22 | 332,262 | — | $0 | 2,909,029 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | X Exercise deriv | 2018-06-22 | 2018-06-22 | 332,262 | — | $0 | 0 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | C Conversion deriv | 2018-06-22 | 2018-06-22 | 12,832,123 | — | $0 | 0 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | C Conversion deriv | 2018-06-22 | 2018-06-22 | 2,909,029 | — | $0 | 0 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | C Conversion | 2018-06-22 | 2018-06-22 | 18,826,417 | — | $0 | 18,826,417 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | F Tax w/h | 2018-06-22 | 2018-06-22 | 211,762 | $17.00 | $3.60M | 18,614,655 | SEC↗ |
| EIDX Eidos Therapeutics, Inc. | P Buy | 2018-06-22 | 2018-06-22 | 1,000,000 | $17.00 | $17.00M | 19,614,655 | SEC↗ |
| CHRS Coherus BioSciences, Inc. | A Award deriv | 2018-02-01 | 2018-02-05 | 20,000 | — | $0 | 20,000 | SEC↗ |
| CHRS Coherus BioSciences, Inc. | A Award deriv | 2017-05-17 | 2017-05-19 | 20,000 | — | $0 | 20,000 | SEC↗ |
| CHRS Coherus BioSciences, Inc. | A Award deriv | 2016-05-24 | 2016-05-26 | 10,000 | — | $0 | 10,000 | SEC↗ |
| CHRS Coherus BioSciences, Inc. | A Award deriv | 2015-04-01 | 2015-04-03 | 20,000 | — | $0 | 20,000 | SEC↗ |
| CHRS Coherus BioSciences, Inc. | A Award deriv | 2015-04-01 | 2015-05-27 | 20,000 | — | $0 | 20,000 | SEC↗ |
| CHRS Coherus BioSciences, Inc. | A Award deriv | 2014-12-31 | 2015-01-02 | 15,000 | — | $0 | 15,000 | SEC↗ |
| CHRS Coherus BioSciences, Inc. | A Award deriv | 2014-11-06 | 2014-11-10 | 14,997 | — | $0 | 14,997 | SEC↗ |